Search results for "25"

showing 10 items of 3263 documents

Immunonutritive Scoring for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Evaluation of the CALLY Index

2021

The novel CRP–albumin–lymphocyte (CALLY) index is an improved immunonutritive scoring system, based on serum C-reactive protein (CRP), serum albumin, and the lymphocyte count. It has shown promise as a prognostic index for patients with hepatocellular carcinoma (HCC) undergoing resections. This study evaluated the prognostic ability of the CALLY index for patients with HCC undergoing transarterial chemoembolization (TACE). We retrospectively identified 280 treatment-naïve patients with HCC that underwent an initial TACE at our institution, between 2010 and 2020. We compared the CALLY index to established risk factors in univariate and multivariate regression analyses for associations with m…

Cancer Researchmedicine.medical_specialtyMultivariate statisticsIndex (economics)Scoring systemFuture studiesMultivariate analysistransarterial chemoembolizationGastroenterologyArticlerisk predictionInternal medicinemedicineOverall survivalRC254-282inflammation indexbusiness.industryfungiUnivariateNeoplasms. Tumors. Oncology. Including cancer and carcinogenshepatocellular carcinomamedicine.diseaseCRP–albumin–lymphocyte ratioimmunoscoringOncologyHepatocellular carcinomabusinessCancers
researchProduct

Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Control…

2021

ObjectivesThe Prognostic Nutritional Index (PNI) and Controlling Nutritional Status (CONUT) score are immunonutritive scoring systems with proven predictive ability in various cancer entities, including hepatocellular carcinoma (HCC). We performed the first evaluation of the CONUT score for patients undergoing transarterial chemoembolization (TACE) and compared CONUT and PNI in the ability to predict median overall survival (OS).MethodsBetween 2010 and 2020, we retrospectively identified 237 treatment-naïve patients with HCC who underwent initial TACE at our institution. Both scores include the albumin level and total lymphocyte count. The CONUT additionally includes the cholesterol level. …

Cancer Researchmedicine.medical_specialtyMultivariate statisticsMultivariate analysisSubgroup analysistransarterial chemoembolizationimmunonutritive scoringGastroenterology03 medical and health sciences0302 clinical medicinecontrolling nutritional statusInternal medicinemedicineIn patientsurvival predictionRC254-282Original Researchrisk scoringbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancerNutritional statushepatocellular carcinomaprognostic nutritional indexmedicine.diseaseBCLC StageOncology030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologybusinessFrontiers in Oncology
researchProduct

The prevalence and characteristics of breakthrough cancer pain in patients receiving low doses of opioids for background pain

2021

Simple Summary The aim of this study was to assess the prevalence and characteristics of breakthrough cancer pain (BTcP) in patients receiving low doses of opioids for background pain. This prospective study showed that in this population, BTcP prevalence was 69.8%. Many patients did not achieve a sufficient level of satisfaction with BTcP medications, particularly with oral morphine. Data also suggest that better optimization of background analgesia, though apparently acceptable, may limit the number of BTcP episodes. Abstract The aim of this study was to assess the prevalence and characteristics of breakthrough cancer pain (BTcP) in patients receiving low doses of opioids for background p…

Cancer Researchmedicine.medical_specialtyPain relieflcsh:RC254-282ArticleCONSECUTIVE SAMPLE03 medical and health sciences0302 clinical medicineAnalgesic therapyInternal medicineEpidemiologymedicineIn patientOral morphinebreakthrough cancer pain; opioids; dosesbusiness.industryLow doseBreakthrough cancer painlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensdosesOpioidsOncologyDose030220 oncology & carcinogenesisCancer painbusiness030217 neurology & neurosurgery
researchProduct

Episodic Breathlessness with and without Background Dyspnea in Advanced Cancer Patients Admitted to an Acute Supportive Care Unit

2020

Aim: To characterize episodic breathlessness (EB) in patients with advanced cancer, and to determine factors influencing its clinical appearance. Methods: A consecutive sample of advanced cancer patients admitted to an acute palliative care unit was surveyed. Continuous dyspnea and EB were measured by a numerical scale. The use of drugs used for continuous dyspnea and EB was recorded. Patients were asked about the characteristics of EB (frequency, intensity, duration and triggers). The Multidimensional dyspnea profile (MDP), the Brief dyspnea inventory (BDI), the Athens sleep scale (AIS) and the Hospital Anxiety and Depression Scale (HADS) were also administered. Results: From 439 advanced …

Cancer Researchmedicine.medical_specialtyPalliative careEpisodic breathlessneOpioidHospital Anxiety and Depression Scalelcsh:RC254-282ArticleCONSECUTIVE SAMPLE03 medical and health sciences0302 clinical medicineInternal medicineMedicineadvanced cancerIn patient030212 general & internal medicinepalliative carebusiness.industryopioidsClinical appearancedyspneaPalliative care.lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensAdvanced cancerConfidence intervalrespiratory tract diseasesepisodic breathlessnessOncology030220 oncology & carcinogenesisbusinessCancers
researchProduct

Preoperative CT-Based Deep Learning Model for Predicting Risk Stratification in Patients With Gastrointestinal Stromal Tumors.

2021

ObjectiveTo develop and evaluate a deep learning model (DLM) for predicting the risk stratification of gastrointestinal stromal tumors (GISTs).MethodsPreoperative contrast-enhanced CT images of 733 patients with GISTs were retrospectively obtained from two centers between January 2011 and June 2020. The datasets were split into training (n = 241), testing (n = 104), and external validation cohorts (n = 388). A DLM for predicting the risk stratification of GISTs was developed using a convolutional neural network and evaluated in the testing and external validation cohorts. The performance of the DLM was compared with that of radiomics model by using the area under the receiver operating char…

Cancer Researchmedicine.medical_specialtyReceiver operating characteristicbusiness.industryDeep learningClass activation mappingNeoplasms. Tumors. Oncology. Including cancer and carcinogensrisk assessmentdeep learningX-ray computedtomographyConfidence intervalprediction modelgastrointestinal stromal tumorsOncologyRisk stratificationCohortMedicineIn patientRadiologyArtificial intelligencebusinessRisk assessmentRC254-282Original ResearchFrontiers in oncology
researchProduct

Survey of Fertility Preservation Options Available to Patients With Cancer Around the Globe

2020

Purpose Oncofertility focuses on providing fertility and endocrine-sparing options to patients who undergo life-preserving but gonadotoxic cancer treatment. The resources needed to meet patient demand often are fragmented along disciplinary lines. We quantify assets and gaps in oncofertility care on a global scale. Methods Survey-based questionnaires were provided to 191 members of the Oncofertility Consortium Global Partners Network, a National Institutes of Health–funded organization. Responses were analyzed to measure trends and regional subtleties about patient oncofertility experiences and to analyze barriers to care at sites that provide oncofertility services. Results Sixty-three res…

Cancer Researchmedicine.medical_specialtyReferralmedia_common.quotation_subjectBest practiceMEDLINEFertilitylcsh:RC254-282Cost EffectivenessFertilidade03 medical and health sciences0302 clinical medicineSupportive Care and Quality of LifeJournal ArticleQuality of CareMedicineFertility preservationmedia_commonOncofertilityEthicsMedicine(all)Response rate (survey)030219 obstetrics & reproductive medicinebusiness.industryHealth Services and OutcomesORIGINAL REPORTSlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensSupportive CarePolicy AnalysisWomen's cancers Radboud Institute for Health Sciences [Radboudumc 17]3. Good healthFertilityOncology030220 oncology & carcinogenesisFamily medicineScale (social sciences)Quality of Life/dk/atira/pure/researchoutput/pubmedpublicationtype/D016428business
researchProduct

Survey of third-party parenting options associated with fertility preservation available to patients with cancer around the globe

2018

Purpose In the accompanying article, “Survey of Fertility Preservation Options Available to Patients With Cancer Around the Globe,” we showed that specific fertility preservation services may not be offered at various sites around the world because of cultural and legal barriers. We assessed global and regional experiences as well as the legal status of third-party reproduction and adoption to serve as a comprehensive international data set and resource for groups that wish to begin oncofertility interventions. Methods We provide data on the legalities of third-party assisted reproductive technologies and other family-building options in the 28 oncofertility-practicing countries surveyed. R…

Cancer Researchmedicine.medical_specialtyResource (biology)fertility preservationPsychological interventionMEDLINEGlobeReproductive technologylcsh:RC254-28203 medical and health sciences0302 clinical medicineSupportive Care and Quality of LifeNeoplasmsSurveys and QuestionnairesOriginal ReportsJournal ArticlemedicineGlobal healthHumansFertility preservationReferral and ConsultationCancerOncofertility030219 obstetrics & reproductive medicineParentingbusiness.industryHealth Services and OutcomesPublic relationslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensWomen's cancers Radboud Institute for Health Sciences [Radboudumc 17]3. Good healthSurgerymedicine.anatomical_structureOncology030220 oncology & carcinogenesis/dk/atira/pure/researchoutput/pubmedpublicationtype/D016428businessreproductive medicine
researchProduct

Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications

2021

Simple Summary This review proposes a comprehensive overview of the main prognostic systems for HCC classified as prognostic scores, staging systems, or combined systems. Prognostic systems for HCC are usually compared in terms of homogeneity, monotonicity of gradients, and discrimination ability. However, despite the great number of published studies comparing HCC prognostic systems, it is rather difficult to identify a system that could be universally accepted as the best prognostic scheme for all HCC patients encountered in clinical practice. In order to give a contribute in this topic, we conducted a study aimed at externally validate the MESH score and the CNLC classification using the…

Cancer Researchmedicine.medical_specialtyReviewlcsh:RC254-282Prognostic score03 medical and health sciences0302 clinical medicinemedicineIn patientMedical physicsStaging systemmonotonicity of gradientsSettore MED/12 - Gastroenterologiadiscrimination ability; hepatocellular carcinoma; homogeneity; monotonicity of gradients; prognostic performance; prognostic systembusiness.industryprognostic systemExternal validationMono-tonicity of gradienthepatocellular carcinomamedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensSettore MED/18homogeneityOncology030220 oncology & carcinogenesisHepatocellular carcinomaPopulation data030211 gastroenterology & hepatologyGeneral healthdiscrimination abilityLiver dysfunctionbusinessprognostic performanceCancers
researchProduct

Assessing Preferences in Patients with Head and Neck Squamous Cell Carcinoma: Phase I and II of Questionnaire Development.

2020

Shared-decision making for head and neck squamous cell carcinoma (HNSCC) is challenged by the difficulty to integrate the patient perception of value within the framework of a multidisciplinary team approach. The aim of this study was to develop a questionnaire to assess the preferences of HNSCC patients with respect to the disease trajectory, expected treatment, and toxicities. In accordance with the standardized EORTC Quality of Life Group&rsquo

Cancer Researchmedicine.medical_specialtyScoring criteriaDiseaselcsh:RC254-282Article03 medical and health sciences0302 clinical medicineQuality of lifehead and neck cancer; multimodal therapies; patient preferences; patient priorities; quality of lifeHealth caremedicineIn patient030212 general & internal medicinemultimodal therapiesneoplasmsbusiness.industryHead and neck cancermedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensHead and neck squamous-cell carcinoma3. Good healthstomatognathic diseasesPatient perceptionsOncologypatient prioritiesquality of life030220 oncology & carcinogenesisFamily medicinehead and neck cancerbusinesspatient preferences
researchProduct

Recent Advances in the Treatment of Patients with Multiple Myeloma

2020

Simple Summary The evolving data from trials assessing novel combinations as a part of the frontline and relapse treatment in transplant and non-transplant candidates have markedly improved the anti-myeloma efficacy of the different therapeutic regimens and improved patients’ prognosis. Current treatment objectives are focused to further improve the rate of complete remission, time to progression, progression-free survival and overall survival without increasing toxicity. Besides, different strategies are being developed in the elderly population as this group of patients requires a closer monitoring with individualized, dose-modified regimens to improve tolerability while maintaining their…

Cancer Researchmedicine.medical_specialtyautologous stem cell transplantationmedicine.medical_treatmentHematopoietic stem cell transplantationDiseaseNewly diagnosedReviewlcsh:RC254-282maintenance03 medical and health sciences0302 clinical medicineAutologous stem-cell transplantationmedicinecar-t cellsIntensive care medicineMultiple myelomanovel drugsbusiness.industryrelapsed refractory multiple myelomaearly relapseAdvanced stageImmunotherapymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensClinical trialmultiple myelomalate relapseOncology030220 oncology & carcinogenesisimmunotherapybusinessconsolidation030215 immunologyCancers
researchProduct